Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biolojic Design has developed a proprietary AI-driven platform for designing programmable antibodies with precise molecular effects. Its lead programs target autoimmune and oncological indications. The company’s first AI-designed antibody has reached Phase 2 clinical trials; other programs are preclinical or entering IND-enabling studies. Early data show potential for greater efficacy and lower toxicity compared to traditional drugs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biolojic Design.